Article
Oncogenic levels of mitogen-activated protein kinase (MAPK) signaling of the dinucleotide KRAS2 mutations G12F and GG12-13VC.
Human mutation - 1 Oct 2001
Feldser D M, Kern S E
Abstract excerpt
We previously reported the occurrence of novel dinucleotide mutations of the K-RAS gene (KRAS2) in 2% of pancreatic tumors sampled, but it remained unknown whether these were functional mutations that convert the proto-oncogene to an oncogene, or unselected mutations that might inactivate protein function. In the current study, the functionality of these rare mutations was quantitated via a mitogen-activated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
